SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 6.59 |
| Enterprise Value ($M) | 7.89 |
| Book Value ($M) | 7.98 |
| Book Value / Share | 0.67 |
| Price / Book | 0.83 |
| NCAV ($M) | -4.34 |
| NCAV / Share | -0.36 |
| Price / NCAV | -1.52 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.80 |
| Return on Assets (ROA) | -0.50 |
| Return on Equity (ROE) | -0.91 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.34 |
| Current Ratio | 0.34 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 2.15 |
| Assets | 14.46 |
| Liabilities | 6.48 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Lind Global Fund II LP | 9.90 | 49.35 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 3,266 | 47,790 | 6.83 | |
| 3,671 | 86,810 | 4.23 | |
| 5,399 | 27,222 | 19.83 | |
| 8,098 | 59,799 | 13.54 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| AADI – Aadi Bioscience, Inc. | ABEO – Abeona Therapeutics Inc. |
| ACB – Aurora Cannabis Inc. | ACHV – Achieve Life Sciences, Inc. |
Financial data and stock pages provided by
Fintel.io